Urologix In-Office BPH Therapies to be Featured on In View Hosted by Larry King
Minneapolis, MN (PRWEB) April 02, 2014 -- Urologix, Inc. (OTCQB:ULGX) the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced that it will be featured on the televised series In View, hosted by Larry King. The In View program will air on the Fox Business Network, Saturday April 5th, 2014 at 1:00pm, EDT and PDT. The segment will discuss Benign Prostatic Hyperplasia (BPH) and educate BPH sufferers and their significant others on effective, non-surgical, in-office treatment options as alternatives to BPH medications. Highlights from the upcoming show will be available at http://www.urologix.com.
BPH, also known as enlarged prostate, affects the majority of men as they age and can create irritating symptoms which significantly impact quality of life. This disease continues to be predominantly treated with daily medications. However, research has shown that drugs are not always effective and can produce unpleasant side effects. The In View segment will highlight safe, long-lasting and effective in-office BPH therapies which can be excellent alternatives to chronic medication. Cooled ThermoTherapy™ and Prostiva® RF Therapy, the market leading non-surgical options, have proven their results through numerous clinical studies and are recommended treatment options from the American Urology Association guidelines.
The show features Dr. J. Randolf Beahrs, a board certified urologist and Director of Minimally Invasive Office Procedures at Metro Urology in St. Paul, Minnesota and a BPH patient who underwent a Prostiva RF Therapy procedure. Dr. Beahrs has extensive urologic experience and has treated numerous patients using both Cooled ThermoTherapy and Prostiva RF Therapy.
“I was excited to participate in this feature on Benign Prostate Hyperplasia. It will help educate patients about the disease and provide information on treatment options that can be more effective than medications and avoid their side effects.” stated Dr. Beahrs. “We can now offer state-of-the-art office-based solutions which result in excellent outcomes for our patients and provide a great value for the patient, physician, and healthcare system. “
Visit http://www.beatbph.com to learn more about BPH and other common prostatic conditions and to find a urologist near you.
About Urologix
Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix’s Cooled ThermoTherapy produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva RF Therapy System delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH symptoms. Both of these therapies provide safe, effective and lasting relief of obstruction and symptoms due to BPH. Prostiva is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.
Federal USA law restricts these devices to sale by or on the order of a physician. For more complete information about the benefits, risks and contraindications associated with Cooled ThermoTherapy and Prostiva RF Therapy, please refer to the product labeling which accompanies the device and can be found at http://www.urologix.com.
If you would like more information on this topic, please contact Susan Overby at 763-745-1540 or soverby(at)urologix(dot)com. To learn more about Urologix and its products and services, visit http://www.urologix.com.
The Urologix logo is available at http://www.urologix.com/clinicians/resource-library.php.
Urologix Media Contact
Susan Overby
763-745-1540
soverby(at)urologix(dot)com
Urologix Investor Relations Contact
Brian Smrdel
(763) 475-7696
bsmrdel(at)urologix(dot)com
Susan Overby, Urologix, Inc., +1 (763) 745-1540, [email protected]
Share this article